FU ZHERMEN,ФУ Жермен,SHEFER GABRIEHLE,ШЕФЕР Габриэле,ABER LORIK,АБЕР Лорик,SLIVKOVSKI MARK K.,СЛИВКОВСКИ Марк К.
申请号：
RU2011142281/10
公开号：
RU0002504553C2
申请日:
2010.03.19
申请国别(地区):
RU
年份:
2014
代理人:
摘要：
FIELD: biotechnologies.SUBSTANCE: invention describes versions of bispecific antibodies specifically bound to EGFR and HER3, which contain amino-acid sequences of variable regions of heavy and light chains respectively, SEQ ID NO: 30 and 29 or SEQ ID NO: 28 and 27 or SEQ ID NO: 28 and 29 or contain complementary regions CDR of heavy and light chains of the above sequences of variable regions. The invention describes nucleic acid coding a versions antibody, and a host cell containing the above nucleic acid and used for expression of the anitbody. Immunoconjugate containing antibody versions and cytotoxic agent used for treatment of cancer containing cells that express EGFR and HER3 are presented. A method for obtaining a bispecific antibody, which involves cultivation of a host cell so that an antibody is generated, is described. The invention describes a pharmaceutical composition for treatment of cancer containing EGFR- and HER3-expressing cells, which contains effective amount of bispecific antibody and pharmaceutically acceptable carrier. The invention proposes a treatment method of cancer containing EGFR- and HER3-expressing cells and an inhibition method of biological activity of EGFR and/or HER3 of a specimen, which involve introduction of effective amount of a bispecific antibody. Use of the above antibody in production of a remedy for treatment of cancer, the cells of which express EGFR and HER3, is described.EFFECT: invention allows obtaining bispecific antibodies binding EGFR and HER3, which are not conjugates of two antibodies.22 cl, 33 dwg, 4 tbl, 19 exИзобретение относится к области биотехнологии и иммунологии. Представлены варианты биспецифичных антител, специфически связывающихся с EGFR и HER3, которые содержат аминокислотные последовательности вариабельных областей тяжелой и легкой цепей, соответственно, SEQ ID NO:30 и 29 или SEQ ID NO:28 и 27 или SEQ ID NO:28 и 29 или содержат комплементарные регионы CDR тяжелой и легкой цепей из указанных последова
